Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mirza, MR; Lundqvist, EA; Birrer, M; Christensen, RD; Nyvang, GB; Malander, S; Anttila, M; Werner, TL; Lund, B; Lindahl, G; Hietanen, S; Peen, U; Dimoula, M; Roed, H; Knudsen, AO; Staff, S; Vistisen, AK; Bjorge, L; Maenpaa, JU

Mirza, MR (reprint author), Copenhagen Univ Hosp, Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark.

LANCET ONCOLOGY, 2019; 20 (10): 1409

Abstract

Background Platinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. B......

Full Text Link